Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Finch Therapeutics Group, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Finch Therapeutics Group, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Smisek Jeffery A | Director | 24,383Indirect | Jun 10, 2024 | 0 |
| Blischak Matthew P. | Chief Executive Officer | – | Jun 23, 2023 | 0 |
| Graf Susan E | Director | 5,010 | Jun 9, 2023 | 0 |
| Ferrante Domenic J | Director | – | Jun 9, 2023 | 0 |
| Shumway Chris | Director, 10% Owner | – | Jun 9, 2023 | 0 |
| Haft Nicholas | Director | 4,056,907Indirect | Jun 9, 2023 | 0 |
| Lange Christian H. | Director | – | Jun 9, 2023 | 0 |
| Blaustein Marc | Chief Operating Officer | 27,995 | Feb 23, 2023 | 0 |
| Vittiglio Joseph | Chief Business & Legal Officer | 31,364 | Oct 25, 2022 | 0 |
| Hamood Samuel A | Director | – | Jun 15, 2022 | 0 |
| Viney Joanne L. | Director | – | Jun 15, 2022 | 0 |
| Perry Gregory D | Chief Financial Officer | – | Feb 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 29, 2024 (view filing) | Mar 28 | 1 day | Smisek Jeffery ADirector | SSale | −6.64K | $2.57 | −$17.1K | −100.0%0 after | |
| Mar 29, 2024 (view filing) | Mar 28 | 1 day | Smisek Jeffery ADirector | SSale | −1.60K | $2.61 | −$4.18K | −19.7%6.51K after | |
| Nov 27, 2023 (view filing) | Nov 22 | 5 days | Smisek Jeffery ADirector | SSale | −1.47K | $3.64 | −$5.35K | −18.1%6.64K after | |
| Jun 9, 2023 (view filing)4:15 PM ET | Jun 9 | Same day | Graf Susan EDirector | PPurchase | +5.01K | $0.27 | +$1.35K | New position5.01K after | |
| Feb 23, 2023 (view filing)4:05 PM ET | Feb 21 | 2 days | Blaustein MarcChief Operating Officer | SSale | −4.62K | $0.38 | −$1.76K | −14.2%28.0K after | |
| Oct 25, 2022 (view filing) | Oct 21 | 4 days | Blaustein MarcChief Operating Officer | SSale | −3.64K | $1.39 | −$5.05K | −10.0%32.6K after | |
| Oct 25, 2022 (view filing) | Oct 21 | 4 days | Vittiglio JosephChief Business & Legal Officer | SSale | −3.64K | $1.39 | −$5.05K | −10.4%31.4K after | |
| Dec 22, 2021 (view filing) | Dec 20 | 2 days | Haft NicholasDirector | PPurchaseCommon Stock, $0.001 par value per share | +63.9K | $10.18 | +$650.0K | +1.6%4.06M after |